Recent evidence supports a widespread role for BIRC6 in conferring apoptosis resistance to cancer cells, as indicated by in vitro studies with cells from gliomas [22], lung cancers [23], cervical cancers [19], [21], [24], [25], fibrosarcomas [18], [24], osteosarcomas [21], breast cancers [24], [26] and colon cancers [27]. Here, BIRC6 is linked to lung cancer.